Novartis AG

Roche Holding AG

Amgen Inc.

Companies will get a three-year reprieve from pharmaceutical duties, provided they invest in manufacturing within the U.S.

Nine major pharma companies have made deals with Trump to lower drug prices

Other drug manufacturers may also join the list of companies for the price deal

U.S. to reach drug pricing agreements with Novartis and Roche - Bloomberg

Amazon.com, Inc.

Worthington Enterprises, Inc.

Tesla, Inc.

Lennar Corporation

PayPal Holdings, Inc.

RadNet, Inc.

Pfizer Inc.

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research

Morning in New York: foreign policy news is the market's focus

Pfizer expects revenue and profit to decline in 2026 due to weaker demand for vaccines and other products related to Covid-19. Analysts note that the company is trying to offset the pressure on its performance by cutting costs and increasing investments in research and development, but do not see any significant drivers for the stock's revaluation in the coming year.

Pfizer expects performance to fall due to lower sales of Covid vaccines. Shares fall

Novo Nordisk A/S


The White House also secured reductions in the cost of Wegovy and Pfizer's cancer drug

Novo will cut the price of Ozempic by 71% for older Americans. This will hinder revenue growth

Shares in Novo Nordisk, maker of popular obesity drugs Wegovy and Ozempic, rose 2.4% in Copenhagen trading after it pulled <a href="https://www.globenewswire.com/news-release/2025/11/08/3184043/0/en/Novo-Nordisk-will-not-increase-its-proposal-to-acquire-Metsera-Inc.html">out</a> of the race to buy U.S. healthcare startup Metsera.

Novo stock jumped after it lost a battle for a med-startup. What's the upside?

Novo Nordisk, the maker of obesity drugs Wegovy and Ozempic, and US pharma company Pfizer have improved their offers to buy US startup Metsera, which develops weight-loss drugs. The company itself still considers Novo's offer "more favorable" despite the escalating battle for the deal, the Financial Times <a href="https://www.ft.com/content/ab202cb5-ee27-4257-b2ee-431408c970c1">writes</a>.

Novo Nordisk and Pfizer raise stakes in battle for weight loss drug developer

Palantir Technologies Inc.

Uber Technologies, Inc.

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: stocks switched to correction mode

Pharma companies squabble over a promising startup in the market for weight management products

Pfizer sues Novo Nordisk and Metsera - Oninvest

Advanced Micro Devices, Inc.

Super Micro Computer, Inc.

The US government shutdown is now in its second month and is about to become the longest in history. However, Wall Street does not seem to care: all three major U.S. stock indices reached highs last week. Quotes were supported by the US Federal Reserve rate cut, the de-escalation of trade tensions after the meeting between President Donald Trump and his Chinese counterpart Xi Jinping, as well as the still high interest in stocks related to artificial intelligence, <a href="https://www.barrons.com/articles/palantir-amd-pfizer-robinhood-mcdonalds-stocks-dfd8631b?mod=RTA#:~:text=That%20is%20because,Jinping%20on%20Thursday.">writes</a> Barron's.

Palantir reports, AMD and rare employment data: what to expect for investors this week

Novo Nordisk has entered into a battle with Pfizer over Metsera. Why do they want this biotech startup?

The share price appreciation is giving Wall Street confidence that after a prolonged "winter" in biotech is finally beginning to thaw